Gauge (instrument)

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Retrieved on: 
Wednesday, January 4, 2023

NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Key Points: 
  • NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
  • The U.S. Food and Drug Administration (FDA) assigned NOV03 a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.
  • “NOV03 was specifically developed to address excess tear evaporation and alleviate the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • “These findings reinforce NOV03 as a potential new treatment option that is distinct from anti-inflammatory and immunomodulatory agents.

Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Retrieved on: 
Monday, December 19, 2022

Clinically proven therapy: The Eterna SCS system features Abbott's proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain7 to deliver superior**8 pain relief.

Key Points: 
  • Clinically proven therapy: The Eterna SCS system features Abbott's proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain7 to deliver superior**8 pain relief.
  • "Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience – all key features when selecting the best overall system.
  • For U.S. important safety information on the Abbott Eterna spinal cord stimulation system, visit: https://bit.ly/3Wgpude .
  • Comparison of Spinal Cord Stimulation Waveforms for Treating Chronic Low Back Pain: Systematic Review and Meta-Analysis.

KUS Receives 2021 PACCAR 10 PPM Quality Award

Retrieved on: 
Monday, December 12, 2022

DAVIE, Fla., Dec. 12, 2022 /PRNewswire/ -- KUS Technology Corporation, a leading supplier of the Marine, Vehicle, and Industrial trades, was recognized as the 2021 10 PPM Quality Award winner by PACCAR in 2022.

Key Points: 
  • DAVIE, Fla., Dec. 12, 2022 /PRNewswire/ -- KUS Technology Corporation, a leading supplier of the Marine, Vehicle, and Industrial trades, was recognized as the 2021 10 PPM Quality Award winner by PACCAR in 2022.
  • PACCAR's "10 PPM Program" annually recognizes suppliers who exceed the quality standard,or the equivalent of 10 defective parts for every million components shipped to PACCAR.
  • For 2021, PACCAR recognizes 407 suppliers in 27 countries on five continents for achieving this high level of quality performance.
  • "We are more than honored to be the recipient of PACCAR's 10 PPM Quality Award again in 2021.

KUS Receives 2021 PACCAR 10 PPM Supplier of the Year

Retrieved on: 
Monday, November 28, 2022

DAVIE, Fla., Nov. 28, 2022 /PRNewswire/ -- KUS was recognized as the PACCAR China Supplier of the Year in 2021.

Key Points: 
  • DAVIE, Fla., Nov. 28, 2022 /PRNewswire/ -- KUS was recognized as the PACCAR China Supplier of the Year in 2021.
  • This is the second year in a row that KUS has been recognized as the Supplier of the Year by PACCAR.
  • PACCAR utilizes its comprehensive Supplier Performance Management program (SPM) to evaluate supplier performances in the areas of product development, operations, and aftermarket support, aligning with PACCAR's key business objectives.
  • KUS Americas Inc has been a supplier to PACCAR since 2018 and we are proud to be recognized by PACCAR for our support, ingenuity, and world-class quality products.

KUS Americas, Inc. Receives Navistar 2022 Supplier Excellence Recognition

Retrieved on: 
Monday, November 14, 2022

DAVIE, Fla., Nov. 14, 2022 /PRNewswire/ -- KUS Americas, Inc. announced its recognition for a 2022 Supplier Excellence award of Navistar, Inc., a commercial transportation solutions provider with a vision to accelerate the impact of sustainable mobility.

Key Points: 
  • DAVIE, Fla., Nov. 14, 2022 /PRNewswire/ -- KUS Americas, Inc. announced its recognition for a 2022 Supplier Excellence award of Navistar, Inc., a commercial transportation solutions provider with a vision to accelerate the impact of sustainable mobility.
  • The 2022 Navistar Supplier Excellence Awards recognize suppliers from all around the world in a variety of industries including freight and engineering services, electronics, powertrain and chassis components, and advanced safety systems.
  • In 2022, Navistar updated its Supplier Excellence award categories to include Performance Awards, which honors suppliers for excellence in quality, delivery and cost, and Leadership Awards in five subcategories: quality, innovation, customer service, general procurement and logistics.
  • KUS Americas, Inc. has been a supplier to Navistar since 2015 and we are proud to be recognized by Navistar for our various achievements and continued partnerships.

Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

Retrieved on: 
Thursday, November 3, 2022

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced the completion of enrollment in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

Key Points: 
  • BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced the completion of enrollment in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.
  • The Phase II, multicenter, double-masked, randomized, vehicle-controlled, parallel-group clinical trial (NCT05238597) is designed to evaluate the safety and tolerability as well as explore the efficacy of two doses of A197 ophthalmic solution in 207 patients with dry eye disease.
  • Dry eye disease is best characterized as an immunological response originating from an imbalance in the protective immunoregulatory versus pro-inflammatory pathways of the ocular surface.
  • Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company committed to the development of disease-modifying therapy for ocular surface disease.

KUS Granted the Master of Quality Supplier Award by DTNA

Retrieved on: 
Thursday, November 3, 2022

DAVIE, Fla., Nov. 3, 2022 /PRNewswire/ -- KUS Americas, Inc. , a leading supplier of Marine, Vehicle, and Industrial was granted the 2020 Master of Quality Supplier Award by Daimler Trucks North America (DTNA) in 2021.This is the second year in a row that KUS has been recognized as the Master of Quality Supplier by DTNA.

Key Points: 
  • DAVIE, Fla., Nov. 3, 2022 /PRNewswire/ -- KUS Americas, Inc. , a leading supplier of Marine, Vehicle, and Industrial was granted the 2020 Master of Quality Supplier Award by Daimler Trucks North America (DTNA) in 2021.This is the second year in a row that KUS has been recognized as the Master of Quality Supplier by DTNA.
  • "The award honors the top components and service suppliers to Freightliner and Western Star Trucks.
  • The award-winning suppliers demonstrate dedication to continuous improvement of the quality of their products, support to DTNA and overall performance," according to DTNA.
  • Aaron Irvin Director of Sales and Business Development (KUS Americas, Inc.)said, 'KUS is very pleased to announce that we have been awarded the Daimler Master of Quality award for the second consecutive year.

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Retrieved on: 
Monday, September 26, 2022

The interim data available from Part B include pharmacokinetics, key pharmacodynamic outcomes, and blinded safety data.

Key Points: 
  • The interim data available from Part B include pharmacokinetics, key pharmacodynamic outcomes, and blinded safety data.
  • Pharmacokinetic data from Part A and the first two cohorts of Part B confirmed rapid absorption and dose-related plasma exposure for oral ANEB-001.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder.
  • Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial ( www.clinicaltrials.gov/ct2/show/NCT05282797 ) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration.

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

Retrieved on: 
Thursday, September 8, 2022

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2022.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2022.
  • First Fiscal Quarter and Recent Business Highlights:
    Announced the initiation of the KONFIDENT-S open label extension study for sebetralstat in the on-demand treatment of HAE.
  • First Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended July 31, 2022 or July 31, 2021.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need.

Premia Spine’s TOPS™ Spinal Joint Replacement Shows Potential to Relieve Back Pain and Maintain Mobility Without Adjacent Level Degeneration

Retrieved on: 
Wednesday, September 7, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220907005485/en/
    The TOPS System from Premia Spine.
  • The first and only facet joint replacement system for the lumbar spine, TOPS was developed to provide mobility, stability and durability after decompression for patients with lumbar spinal stenosis and degenerative spondylolisthesis.
  • Premia Spine, a medical technology company, aims to improve the lives of chronic leg and back pain patients with its TOPS System.
  • TOPS is designed to provide lasting mobility, stability and durability to patients with lumbar spinal stenosis, degenerative spondylolisthesis and related spinal conditions.